Nanoformulations: Reach for the (Micro)Sun!
The UK’s Centre for Process Innovation targets easier manufacturing of nanoformulated medicines.
James Strachan |
The market for nanoformulated medicines is growing at a significant rate – with an expected value of $350.8 billion by 2025 (1). There is also an abundance of research taking place in the field. Nanomedicines refer to cargos of therapeutics at the nanoscale and may exist as nanoparticles, nanocrystals or other formulations. Manufacturing nanomedicines – and deciding on the best delivery method – is challenging because of the very thing that makes them special: their nanosize. Indeed, significant issues with reproducibility plague nanomedicines, and there have been high failure rates in translating nanomedicines from the bench to the clinic. Today, a growing focus on microfluidics looks to provide enhanced process control and predictability.
Here, we speak with Caroline Kelly, Technology and Innovation Officer at the UK’s Centre for Process Innovation (CPI), to find out how microfluidics and improved process control can give a boost to the future of nanomedicines.
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!
Login if you already created an account
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine